The Asia Pacific region is expected to make significant contributions to the biologics market in the coming years owing to the developing healthcare sector in the region. Further, the market is anticipated to be driven by the dominance of microbial sources as a major portion of the product range has its source in the microbial expressions system, which are used during the treatment of several chronic diseases depending upon the type of monoclonal antibodies.

Also Read: therapeutic beds market, influenza vaccine market, blockchain technology market